Elix, an AI Drug Discovery Company, and University of Vienna Enter Joint Research ...

Japan-based AI drug discovery company Elix and the University of Vienna have entered a joint research agreement to accelerate drug discovery by integrating AI-driven molecular design with advanced NMR spectroscopy. The collaboration targets traditionally undruggable proteins, aiming to improve drug design efficacy and reduce development costs for complex diseases such as cancer.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 3 sources have reported it between 29 Jul 2026 and 3 Aug 2026.